Intravenous Immunoglobulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Intravenous Immunoglobulin Market Report Segments the Industry Into by Type (IgG, Iga, Igm, and Others), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency, and More), End User (Hospitals, Specialty Clinics & Neurology Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Intravenous Immunoglobulin Market Size and Share

Global Intravenous Immunoglobulin Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Global Intravenous Immunoglobulin Market Analysis by Mordor Intelligence

The intravenous immunoglobulin market size reached USD 16.31 billion in 2025 and is forecast to climb to USD 23.89 billion by 2030, translating into a 7.93% CAGR, which keeps the intravenous immunoglobulin market among the most resilient plasma-derived therapeutic spaces[1]Takeda Pharmaceutical Company, “GAMMAGARD LIQUID FDA Expansion,” takeda.com. Rising clinical use beyond primary immunodeficiency, demographic ageing, and sustained capacity investments by fractionators all reinforce demand fundamentals. North America leads the intravenous immunoglobulin market because of well-established reimbursement pathways and high per-capita spending, whereas rapid healthcare access gains and policy reform propel Asia-Pacific. IgG retains dominant status, and expanding neurological indications such as chronic inflammatory demyelinating polyneuropathy broaden the intravenous immunoglobulin market opportunity landscape[2]Octapharma USA, “IVIG Specialty Clinic Trends,” octapharmausa.com.

Key Report Takeaways

  • By immunoglobulin class, IgG captured 74.75% of the intravenous immunoglobulin market share in 2024; it is also projected to expand at an 8.54% CAGR through 2030.
  • By application, hypogammaglobulinemia accounted for 32.43% share of the intravenous immunoglobulin market size in 2024, while myasthenia gravis is advancing at an 8.23% CAGR to 2030.
  • By end user, hospitals held 44.35% revenue share in 2024; specialty clinics and neurology centers are forecast to grow fastest at an 8.61% CAGR through 2030.
  • By geography, North America led with 42.34% revenue share in 2024, whereas Asia-Pacific is projected to accelerate at an 8.45% CAGR to 2030.

Segment Analysis

By Immunoglobulin Class: IgG Dominance Drives Innovation

IgG commanded 74.75% of the intravenous immunoglobulin market in 2024, and the segment is growing at an 8.54% CAGR to 2030, which underlines how indispensable IgG remains for both replacement and immunomodulation. Grifols’ purification process consistently delivers ≥98% IgG purity, strengthening brand differentiation. High-strength formulations now shorten infusion time, easing hospital scheduling pressures and improving patient comfort.

Manufacturers have prioritized continuous chromatography to boost yield and lower cost, which further bolsters margins across the intravenous immunoglobulin market. Regulatory clearances for new brands such as Yimmugo and ALYGLO increase competitive dynamics yet simultaneously assure broader supply security. IgA and IgM retain niche status focused on mucosal and complement-mediated disorders.

Intravenous Immunoglobulin Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Neurological Indications Accelerate Growth

Hypogammaglobulinemia retained the largest share at 32.43% of the intravenous immunoglobulin market size in 2024, reflecting entrenched prescribing habits and clear guidelines. Nevertheless, myasthenia gravis is charting an 8.23% CAGR, the quickest among tracked indications, as neurologists adopt IVIG earlier in the disease course.

Chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy also post solid gains, benefiting from recent label expansions. Off-label niches such as autoimmune encephalitis imply additional upside for the intravenous immunoglobulin market as clinical evidence accumulates and payers refine reimbursement conditions.

By End User: Specialty Care Transformation

Hospitals delivered 44.35% of revenue in 2024, preserving leadership within the intravenous immunoglobulin market because most first infusions still happen in acute settings. However, specialty clinics and neurology centers are accelerating fastest, posting an 8.61% CAGR as payers and patients value dedicated infusion expertise.

Specialist sites streamline dosing adjustments, manage adverse events, and integrate electronic monitoring, which lifts adherence and outcome metrics. Home-care programs, while smaller, continue to emerge, encouraged by device advances and telehealth support that reduce facility visits and total cost of care.

Intravenous Immunoglobulin Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America kept 42.34% of the intravenous immunoglobulin market in 2024 due to long-standing insurer coverage and extensive plasma collection infrastructure. Medicare policies outline usage criteria that commercial payers largely mirror, facilitating predictable demand and rapid adoption of new formulations. Specialized infusion networks and maturing home-based services advance patient convenience and operational efficiency.

Asia-Pacific is growing fastest at an 8.45% CAGR through 2030. China’s National Reimbursement Drug List negotiations produced average IVIG price reductions of 63% in 2024, opening therapy to previously unreachable cohorts. Japan’s revised health technology assessments uphold funding for innovative biologics, while India’s production-linked incentives stimulate local fractionation capacity, all of which enlarge the intravenous immunoglobulin market base.

Europe shows stable progression, yet supply dependence on United States plasma highlights vulnerability. ESG-driven self-sufficiency policies and centralized procurement place pressure on manufacturers to diversify donor pools and enhance transparency. Gradual shifts toward outpatient infusions aim to reduce hospitalization costs and maintain quality benchmarks across the intravenous immunoglobulin market.

Intravenous Immunoglobulin Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The intravenous immunoglobulin market is moderately concentrated, as Takeda, CSL Behring, and Grifols control integrated collection-to-product chains that protect margins and secure supply. Each invests in continuous processing technology to lift yields and deploy digital twins for predictive maintenance. Strategic moves include CSL’s rollout of a novel nomogram-based plasma collection system that increases volume per donation by about 10% while maintaining safety[3]CSL Limited, “Rika Plasma Donation System,” csl.com.

Joint ventures broaden reach and hedge capacity risk. ICU Medical and Otsuka’s USD 200 million partnership builds one of the largest IV solutions plants in North America, supporting downstream bottling for immunoglobulins. Grifols seeks optionality through recombinant polyclonal platforms after winning BARDA funding, an approach that could Eventually reshape supply economics and lessen plasma reliance.

Emerging regional firms leverage government incentives to establish fractionation hubs close to high-growth patient pools. Nonetheless, high capital commitments, donor access hurdles, and complex regulatory files form substantial entry barriers, sustaining existing leadership within the intravenous immunoglobulin market.

Global Intravenous Immunoglobulin Industry Leaders

  1. Biotest AG

  2. Kedrion S.p.A

  3. Grifols, S.A.

  4. Bio Products Laboratory Limited

  5. Takeda Pharmaceutical Company Limited

  6. *Disclaimer: Major Players sorted in no particular order
Intravenous Immunoglobulin Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • November 2024: ICU Medical and Otsuka Pharmaceutical Factory formed a USD 200 million joint venture that targets annual output of 1.4 billion IV solution units to enhance supply resilience.
  • October 2024: GigaGen secured a USD 135.2 million BARDA contract to advance recombinant polyclonal therapies against botulinum neurotoxins, signaling strategic expansion beyond plasma-derived products.
  • July 2024: Grifols received FDA sign-off for expanded XEMBIFY labeling that allows treatment-naïve primary immunodeficiency patients to start with subcutaneous dosing.
  • June 2024: Biotest obtained FDA approval for Yimmugo, its first US-market intravenous immunoglobulin, strengthening competitive diversity

Table of Contents for Global Intravenous Immunoglobulin Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Geriatric Population
    • 4.2.2 Increased Adoption of Immunoglobulin Therapy
    • 4.2.3 Rising Prevalence of Immunodeficiency & Bleeding Disorders
    • 4.2.4 Advancements in Plasma-fractionation Technology
    • 4.2.5 Off-label Neuro­logical Use & Relaxed Reimbursement in Asia
    • 4.2.6 Regional Plasma-collection Hubs Driving Supply Security
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Approval & Donor-screening Norms
    • 4.3.2 High Therapy & Cold-chain Costs
    • 4.3.3 Shift toward Subcutaneous Ig (SCIG) Reducing IVIG Volumes
    • 4.3.4 ESG Scrutiny of Plasma Sourcing Raising Compliance Costs
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value - USD)

  • 5.1 By Immunoglobulin Class
    • 5.1.1 IgG
    • 5.1.2 IgA
    • 5.1.3 IgM
    • 5.1.4 Others
  • 5.2 By Application
    • 5.2.1 Hypogammaglobulinemia
    • 5.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 5.2.3 Primary Immunodeficiency Diseases (PID)
    • 5.2.4 Myasthenia Gravis
    • 5.2.5 Multifocal Motor Neuropathy
    • 5.2.6 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specialty Clinics & Neurology Centers
    • 5.3.3 Home-Care Settings
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles
    • 6.3.1 Takeda Pharmaceutical Co.
    • 6.3.2 CSL Behring
    • 6.3.3 Grifols SA
    • 6.3.4 Octapharma AG
    • 6.3.5 Baxter International Inc.
    • 6.3.6 Kedrion SpA
    • 6.3.7 Biotest AG
    • 6.3.8 Bio Products Laboratory Ltd
    • 6.3.9 LFB Group
    • 6.3.10 China Biologic Products Holdings
    • 6.3.11 Shanghai RAAS Blood Products
    • 6.3.12 Hualan Biological Engineering
    • 6.3.13 ADMA Biologics Inc.
    • 6.3.14 Emergent BioSolutions Inc.
    • 6.3.15 Kamada Ltd
    • 6.3.16 GC Pharma
    • 6.3.17 Intas Pharmaceuticals (Lonza Tie-up)
    • 6.3.18 BioTest Pharma (US)
    • 6.3.19 South African National Blood Service
    • 6.3.20 Sanquin Plasma Products
  • *List Not Exhaustive

7. Market Opportunities & Future Outlook

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Intravenous Immunoglobulin Market Report Scope

As per the scope of this report, intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS, measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into a muscle, a vein, or under the skin. The intravenous immunoglobulin market is segmented by type (IgG, IgA, IgM, IgE, and IgD), application (hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for all the above segments.

By Immunoglobulin Class IgG
IgA
IgM
Others
By Application Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Diseases (PID)
Myasthenia Gravis
Multifocal Motor Neuropathy
Other Applications
By End User Hospitals
Specialty Clinics & Neurology Centers
Home-Care Settings
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-pacific China
Japan
India
Australia
South Korea
Rest of Asia-pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Immunoglobulin Class
IgG
IgA
IgM
Others
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Diseases (PID)
Myasthenia Gravis
Multifocal Motor Neuropathy
Other Applications
By End User
Hospitals
Specialty Clinics & Neurology Centers
Home-Care Settings
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-pacific China
Japan
India
Australia
South Korea
Rest of Asia-pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the intravenous immunoglobulin market?

The intravenous immunoglobulin market size is USD 16.31 billion in 2025 and is projected to reach USD 23.89 billion by 2030.

Which immunoglobulin class dominates sales?

IgG accounts for 74.75% of revenue because its pharmacology suits both replacement and immunomodulatory therapy.

Which region is growing fastest for IVIG?

Asia-Pacific posts the quickest growth at an 8.45% CAGR, driven by ageing populations, policy reform, and larger reimbursement pools.

Why are specialty clinics gaining share in IVIG delivery?

Clinics focused on neurology and immunology streamline infusion protocols, improve monitoring, and deliver better patient experience, supporting an 8.61% CAGR.

How does SCIG adoption affect IVIG demand?

Subcutaneous products offer convenience and fewer systemic side effects, which moderates IVIG volume growth, especially in North America and Europe.

What are key restraints for market expansion?

High therapy costs, cold-chain logistics, and stringent donor-screening rules increase operational overhead and can limit patient access in price-sensitive regions.

Global Intravenous Immunoglobulin Market Report Snapshots

Compare market size and growth of Global Intravenous Immunoglobulin Market with other markets in Healthcare Industry

Access Report long-arrow-right